Personalized medicine in haematooncology – the pathologist’s perspective
Authors:
Vít Campr
Authors place of work:
Univerzita Karlova v Praze, 2. lékařská fakulta, Ústav patologie a molekulární medicíny FN Motol
Published in the journal:
Čas. Lék. čes. 2010; 149: 464-467
Category:
Review Article
Pojem personalizovaná medicína nesplývá pouze s individualizovaným terapeutickým přístupem k pacientovi, jeho nutným předpokladem je i individualizovaný přístup k diagnóze. Většina onkologických diagnóz a řada nepostradatelných prognostických znaků je stanovena patology. Patolog má kromě základních histologických metod k dispozici i přístupy morfoproteomické a morfogenomické. Nedílnou součástí soudobé onkologické diagnózy je molekulární vyšetření nádoru, které může prokázat přítomnost molekuly vhodné k cílené terapii a vést k tvorbě molekulárního “pacient-specifického” znaku sloužícího ke sledování minimální reziduální nemoci.
Summary
The concept of personalized medicine is not only an individualized therapeutic management of a patient; its prerequisite is an individualized approach to diagnosis. Most of oncological diagnoses and a many prognostic features are provided by a pathologists. The pathologist uses not only basic histological methods, but also a morphoproteomic and morphogenomic approaches. Integral part of a contemporary oncological diagnosis is a molecular investigation of a tumour, which can both prove the presence of molecules suitable for targeted therapy, and design a molecular “patient-specific” marker for minimal residual disease monitoring.
Key words:
personalized medicine, haematopathology, diagnosis, minimal residual disease.
Zdroje
1. Chan JKC, Banks PM, Cleary ML, Delsol G, de Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Harris NL, Isaacson PG, Jaffe ES, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Stein H, Warnke RA. A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). Histopathology 1994; 25: 517–536.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
3. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163–208.
4. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Eds.) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Lyon: IARC Press 2008.
5. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla- Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861.
6. Sobin LH, Gospodarowicz MK, Wittekind C (Eds.) TNM Classification of Malignant Tumours, 7th Edition. Wiley-Blackwell 2009.
7. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971; 31: 1860–1861.
8. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.
9. Kodet R, Mrhalová M, Krsková L, Stejskalová E. Anaplastický velkobuněčný lymfom: přehled problematiky. Čes.-slov. Patol 2003; 39: 102–114.
10. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group. CHOP- like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good – prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391.
11. Chamuleau MED, van de Loosdrecht AA, Huijgens PC. Monoclonal antibody therapy in haematological malignancies. Curr Clin Pharmacol 2010; 5: 148–159.
12. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373–2380.
13. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.
14. Mand’áková P, Campr V, Kodet R. Korelace výsledků průtokové cytometrie a morfologických nálezů v diagnostice maligních lymfomů z B buněk. Čas Lék čes 2003; 142: 651–655.
15. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, van Krieken JH, Droese J, González D, Bastard C, White HE, Spaargaren M, González M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED – 2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317.
16. Mrhalová M, Krsková L, Kalinová M, Soukup J, Kodet R. Folikulární lymfomy: molekulární diagnostika t(14;18)(q32;q21) – fluorescenční in situ hybridizace, kvalitativní a kvantitativní PCR. Čes.-slov. Patol 2003; 39: 130–137.
17. Kodet R, Mrhalová M, Krsková L, Soukup J, Campr V, Neskudla T, Szépe P, Plank L. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Arch 2003; 442: 538–547.
18. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V, Plonquet A, Siebert R, Callet-Bauchu E, Andersen N, van Dongen JJ, Klapper W, Berger F, Ribrag V, van Hoof AL, Trneny M, Walewski J, Dreger P, Unterhalt M, Hiddemann W, Kneba M, Kluin-Nelemans HC, Hermine O, Macintyre E, Dreyling M. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215–3223.
19. Kalinová M, Krsková L, Břízová H, Kabíčková E, Kepák T, Kodet R. Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma – residual disease monitoring and a correlation with the disease status. Leuk Res 2008; 32: 25–32.
20. Břízová H, Kalinová M, Krsková L, Mrhalová M, Kodet R. Quantitative Measurement of Cyclin D1 mRNA, a Potent Diagnostic Tool to Separate Mantle Cell Lymphoma From Other B-cell Lymphoproliferative Disorders. Diagn Mol Pathol 2008; 17: 39–50.
21. Břízová H, Kalinová M, Krsková L, Mrhalová M, Kodet R. Quantitative monitoring of cyclin D1 expression: A molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma. Int J Cancer 2008; 132: 2865–2870.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric clinical oncology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Haematology Vascular surgery Clinical oncology Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole vs. Tramadol in Postoperative Analgesia
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Significance of TDM, phenotyping and genotyping for the correct drug dosage
- Hereditary thrombophilias – recommendations for genetic testing in the clinical praxis
- Pharmacogenetic aspects of current pharmacotherapy
- Pharmacogenetics in cardiovascular diseases therapy – treatment according guidelines or according the individual requirement?